Across TCGA pan-cancer cohorts, ATP6V0C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP6V0C data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATP6V0C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP6V0C expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where ATP6V0C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.871	0.573	.021	5	view →
LUAD	DFS	Median	II,III,IV	0.174	1.000	.024	3	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.908	.035	1	view →
CCRCC	OS	Quartile	II,III,IV	0.592	0.899	.037	1	view →
LSCC	DFS	Median	II,III,IV	0.749	0.889	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ATP6V0C tumor-vs-normal RNA expression · all ATP6V0C data types